B4Deals
Catalent deal closes: three fill-finish plants pass to Novo Nordisk
Novo Holdings completed its $16.5 billion purchase of contract maker Catalent and sold three of its plants to Novo Nordisk for about $11 billion.
Dateline
Anagni
Catalent site in Swindon, UK (not one of the three plants in the deal) Photo: Lewis Clarke, CC BY-SA 2.0, via Wikimedia Commons (cropped)
In one lineNovo bought running filling lines instead of waiting years to build them.
What happened
Novo Holdings, the foundation-owned investor that controls Novo Nordisk, completed its purchase of Catalent, a large contract drug maker, for about $16.5 billion. The deal was first announced in February 2024 and went through competition reviews in the US and Europe.
The three plants
As agreed, Novo Nordisk bought three Catalent fill-finish sites for about $11 billion: Anagni in Italy, Bloomington in Indiana and Brussels in Belgium. These plants fill sterile drugs into vials, syringes and cartridges.
Why buy instead of build
A new sterile plant can take four years or more from first spade to first approved lot. A running plant already has staff, clean rooms and regulatory approvals, so new products can be transferred in faster.
Who objected
Some customers and rivals worried that contract capacity used by many companies would now serve one. Regulators cleared the deal; Novo said existing customer contracts would be honoured.
The caveat
Novo did not say how much of each site would switch to its own medicines, or how fast.
What it changes for supply
The three sites were already filling medicines. Buying them shifts capacity to Novo immediately, though converting lines to new products still takes time.
Still open
How quickly the lines move over to Novo products, and what happens to other companies that used to fill at these sites.
SourceNovo Holdings and Novo Nordisk statements, December 2024
Peptide Global covers how medicines are made and traded. Nothing here is medical advice.
